FDA Approves First And Only Twice-Yearly Schizophrenia Drug

by Vandana Singh, Benzinga Editor

September 1, 2021 12:30 PM | 1 min read |

The FDA has approved a long-acting schizophrenia drug from Janssen, a unit of Johnson & Johnson JNJ
Previously known as paliperidone palmitate, Invega Hafyera is a twice-yearly injectable. It's the first and only twice-yearly med for the condition.
The new long-acting regime joins J&J's existing one-month and three-month formulations, dubbed Invega Sustenna and Invega Trinza, respectively, plus a two-week injection known as Risperdal Consta.
The FDA based its approval on the results from a 702-patient Phase 3 trial. In that study, investigators found that the six-month formulation's performance held up with those already using the three-month injection to avoid relapse.
Related content: Benzinga's Full FDA Calendar.
Price Action: JNJ shares are up 0.10% at $173.30 during the market session on the last check Wednesday.

Posted In:

Biotech News Health Care FDA General Briefs Schizophrenia

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.